{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T06:26:47Z","timestamp":1789712807388,"version":"4.0.1"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,4,1]]},"DOI":"10.1093\/jac\/dkh555","type":"journal-article","created":{"date-parts":[[2005,2,25]],"date-time":"2005-02-25T01:30:49Z","timestamp":1109295049000},"page":"417-419","source":"Crossref","is-referenced-by-count":24,"title":["Progression of liver fibrosis in patients coinfected with hepatitis C virus and human immunodeficiency virus undergoing antiretroviral therapy"],"prefix":"10.1093","volume":"55","author":[{"given":"Juan A.","family":"Pineda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Mac\u00edas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2005,4]]},"reference":[{"key":"key\n\t\t\t\t20171010181223_R1","doi-asserted-by":"crossref","unstructured":"Bonacini, M. (2004). Liver injury during highly active antiretroviral therapy: the effect of hepatitis C coinfection. Clinical Infectious Diseases38, Suppl. 2, S104\u20138.","DOI":"10.1086\/381453"},{"key":"key\n\t\t\t\t20171010181223_R2","doi-asserted-by":"crossref","unstructured":"Mac\u00edas, J., Melguizo, I., Fern\u00e1ndez-Rivera, F. J. et al. (2002). Mortality due to liver failure and impact on survival of hepatitis virus infections in HIV-infected patients on potent antiretroviral therapy. European Journal of Clinical Microbiology and Infectious Diseases21, 775\u201381.","DOI":"10.1007\/s10096-002-0823-0"},{"key":"key\n\t\t\t\t20171010181223_R3","doi-asserted-by":"crossref","unstructured":"Mart\u00ednez-Sierra, C., Arizcorreta, A., D\u00edaz, F. et al. (2003). Progression of chronic hepatitis C to liver fibrosis and cirrhosis in patients coinfected with hepatitis C virus and human immunodeficiency virus. Clinical Infectious Diseases36, 491\u20138.","DOI":"10.1086\/367643"},{"key":"key\n\t\t\t\t20171010181223_R4","doi-asserted-by":"crossref","unstructured":"Mohsen, A. H., Easterbrook, P. J., Taylor, C. et al. (2003). Impact of human immunodeficiency virus (HIV) infection on the progression of liver fibrosis in hepatitis C virus infected patients. Gut52, 1035\u201340.","DOI":"10.1136\/gut.52.7.1035"},{"key":"key\n\t\t\t\t20171010181223_R5","doi-asserted-by":"crossref","unstructured":"Mart\u00edn-Carbonero, L., Benhamou, Y., Puoti, M. et al. (2004). Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study. Clinical Infectious Diseases38, 128\u201333.","DOI":"10.1086\/380130"},{"key":"key\n\t\t\t\t20171010181223_R6","doi-asserted-by":"crossref","unstructured":"Mac\u00edas, J., Castellano, V., Merchante, N. et al. (2004). Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine. AIDS18, 767\u201374.","DOI":"10.1097\/00002030-200403260-00007"},{"key":"key\n\t\t\t\t20171010181223_R7","unstructured":"Marcellin, P., Asselah, T. & Boyer, N. (2002). Fibrosis and disease progression in hepatitis C. Hepatology36, Suppl. 1, S47\u2013S56."},{"key":"key\n\t\t\t\t20171010181223_R8","doi-asserted-by":"crossref","unstructured":"Qurishi, N., Kreuzberg, C., Luchters, G. et al. (2003). Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet362, 1708\u201313.","DOI":"10.1016\/S0140-6736(03)14844-1"},{"key":"key\n\t\t\t\t20171010181223_R9","doi-asserted-by":"crossref","unstructured":"Sulkowski, M. S., Thomas, D. L., Mehta, S. H. et al. (2002). Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology35, 182\u20139.","DOI":"10.1053\/jhep.2002.30319"},{"key":"key\n\t\t\t\t20171010181223_R10","doi-asserted-by":"crossref","unstructured":"Dieterich, D. T., Robinson, P. A., Love, J. et al. (2004). Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors. Clinical Infectious Diseases38, Suppl. 2, S80\u20139.","DOI":"10.1086\/381450"},{"key":"key\n\t\t\t\t20171010181223_R11","doi-asserted-by":"crossref","unstructured":"Mart\u00ednez, E., Blanco, J. L., Arnaiz, J. A. et al. (2001). Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS15, 1261\u20138.","DOI":"10.1097\/00002030-200107060-00007"},{"key":"key\n\t\t\t\t20171010181223_R12","doi-asserted-by":"crossref","unstructured":"Mart\u00edn-Carbonero, L., N\u00fanez, M., Gonz\u00e1lez-Lahoz, J. et al. (2003). Incidence of liver injury after beginning antiretroviral therapy with efavirenz or nevirapine. HIV Clinical Trials4, 115\u201320.","DOI":"10.1310\/N4VT-3E9U-4BKN-CRPW"},{"key":"key\n\t\t\t\t20171010181223_R13","doi-asserted-by":"crossref","unstructured":"Sulkowski, M. S. (2004). Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors. Clinical Infectious Diseases38, Suppl. 2, S90\u20137.","DOI":"10.1086\/381444"},{"key":"key\n\t\t\t\t20171010181223_R14","unstructured":"Anon. (2001). Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures\u2014worldwide, 1997\u20132002. Morbidity and Mortality Weekly Report49, 1153\u20136."},{"key":"key\n\t\t\t\t20171010181223_R15","doi-asserted-by":"crossref","unstructured":"Tural, C., Fuster, D., Tor, J. et al. (2003). Time on antiretroviral therapy is a protective factor for liver fibrosis in HIV and hepatitis C virus (HCV) co-infected patients. Journal of Viral Hepatitis10, 118\u201325.","DOI":"10.1046\/j.1365-2893.2003.00413.x"},{"key":"key\n\t\t\t\t20171010181223_R16","doi-asserted-by":"crossref","unstructured":"Benhamou, Y., Martino, V., Bochet, M. et al. (2001). Factors affecting liver fibrosis in human immunodeficiency virus- and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. Hepatology34, 283\u20137.","DOI":"10.1053\/jhep.2001.26517"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/55\/4\/417\/2399142\/dkh555.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,10,11]],"date-time":"2017-10-11T00:41:07Z","timestamp":1507682467000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/jac\/article\/55\/4\/417\/800970\/Progression-of-liver-fibrosis-in-patients"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,4,1]]},"references-count":16,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2005,4]]},"published-print":{"date-parts":[[2005,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkh555","relation":{},"ISSN":["1460-2091","0305-7453"],"issn-type":[{"value":"1460-2091","type":"electronic"},{"value":"0305-7453","type":"print"}],"subject":[],"published-other":{"date-parts":[[2005,4]]},"published":{"date-parts":[[2005,4,1]]}}}